We are live on ! Find out more

2,525 hedge funds and large institutions have $157B invested in Pfizer in 2019 Q4 according to their latest regulatory filings, with 311 funds opening new positions, 1,008 increasing their positions, 970 reducing their positions, and 77 closing their positions.

New
Increased
Maintained
Reduced
Closed

304% more first-time investments, than exits

New positions opened: 311 | Existing positions closed: 77

32% more funds holding in top 10

Funds holding in top 10: 81107 (+26)

10% more capital invested

Capital invested by funds: $142B → $157B (+$14.4B)

9% more funds holding

Funds holding: 2,3232,525 (+202)

4% more repeat investments, than reductions

Existing positions increased: 1,008 | Existing positions reduced: 970

0.55% more ownership

Funds ownership: 75.55%76.09% (+0.55%)

16% less call options, than puts

Call options by funds: $1.19B | Put options by funds: $1.41B

Holders
2,525
Holders Change
+202
Holders Change %
+8.7%
% of All Funds
49.74%
Holding in Top 10
107
Holding in Top 10 Change
+26
Holding in Top 10 Change %
+32.1%
% of All Funds
2.11%
New
311
Increased
1,008
Reduced
970
Closed
77
Calls
$1.19B
Puts
$1.41B
Net Calls
-$224M
Net Calls Change
+$45.8M
Name Holding Trade Value Shares
Change
Change in
Stake
LNC
1001
Lincoln National Corp
Pennsylvania
$2.98M +$97.1K +2,725 +4%
BHB
1002
Bank Hapoalim BM
Israel
$2.96M -$160K -4,505 -5%
FNBTCON
1003
First National Bank & Trust Co of Newtown
Pennsylvania
$2.96M -$37.5K -1,054 -1%
SLG
1004
Stanley-Laman Group
Pennsylvania
$2.95M -$140K -3,930 -5%
AC
1005
Abbrea Capital
California
$2.94M -$93.3K -2,619 -3%
OCM
1006
Orleans Capital Management
Louisiana
$2.93M -$20.6K -579 -0.7%
Walleye Trading
1007
Walleye Trading
New York
$2.92M +$2.8M +78,622 New
ACA
1008
Aptus Capital Advisors
Alabama
$2.92M -$665K -18,670 -19%
IMOV
1009
Investment Management of Virginia
Virginia
$2.92M -$83.1K -2,333 -3%
AAM
1010
Auxier Asset Management
Oregon
$2.91M -$31.4K -881 -1%
HIP
1011
Harrell Investment Partners
Texas
$2.89M +$2.77M +77,837 New
WSC
1012
Wellington Shields & Co
New York
$2.89M +$2.07M +57,976 +293%
AWM
1013
Argent Wealth Management
Massachusetts
$2.89M +$2.77M +77,736 New
IWM
1014
IHT Wealth Management
Illinois
$2.89M +$60K +1,685 +2%
CC
1015
Chicago Capital
Illinois
$2.89M -$24.8K -696 -0.9%
CMO
1016
Covenant Multifamily Offices
Texas
$2.89M +$1.03M +28,980 +85%
LCP
1017
Legacy Capital Partners
Wisconsin
$2.88M +$20.6K +579 +0.8%
SIMM
1018
Stillwater Investment Management (Minnesota)
Minnesota
$2.88M +$94.1K +2,642 +4%
FMBTD
1019
First Midwest Bank Trust Division
Illinois
$2.85M +$19.7K +553 +0.7%
OPTFSNA
1020
Old Point Trust & Financial Services N A
Virginia
$2.85M -$80.7K -2,265 -3%
PI
1021
PEAK6 Investments
Illinois
$2.83M +$2.34M +65,759 +639%
BCM
1022
Brooktree Capital Management
Michigan
$2.83M +$2.71M +76,042 New
GP
1023
Girard Partners
Pennsylvania
$2.83M +$36K +1,010 +1%
GSBTD
1024
Glenview State Bank Trust Department
Illinois
$2.82M -$125K -3,499 -4%
TIM
1025
Thompson Investment Management
Wisconsin
$2.82M +$84.6K +2,375 +3%

PFE Hedge Fund Activity: Q4 2019 in Review

2,525 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q4 2019, worth a combined $157B — up 10% from $142B a quarter earlier.

Buyers outnumbered sellers: 311 funds opened new PFE positions and 77 closed out — a net gain of 234 holders — while 1,008 added to existing stakes and 970 trimmed.

The largest buyer was Capital World Investors, adding an estimated $835M. The largest seller was JP Morgan Chase, cutting an estimated $1.43B.

  • 2,525 institutional investors held Pfizer (PFE) as of Q4 2019, up from 2,323 in Q3 2019.
  • Funds reported $157B of Pfizer stock for Q4 2019, up 10% quarter-over-quarter.
  • 311 funds opened new Pfizer positions in Q4 2019 and 77 closed out, a net change of +234 holders.
  • The largest Pfizer buyer in Q4 2019 was Capital World Investors, an estimated $835M added.
  • The largest Pfizer seller in Q4 2019 was JP Morgan Chase, an estimated $1.43B sold.

Based on aggregated 13F filings for Q4 2019.